Stocks/GMAB/Filings & Earnings

GMAB SEC Filings, Earnings & Splits

Key events from SEC filings, earnings beat/miss history, stock split records, and share float data for GMAB.

What are GMAB's recent SEC filings?

6-K · OtherNov 12, 2026

Genmab A/S filed a Form 6-K with the SEC to furnish a company announcement dated November 10, 2026. The filing itself contains only the cover page and exhibit index, with the substantive content of the announcement not included in the provided text.

View full filing details →
6-K · OtherNov 12, 2026

Genmab A/S filed a Form 6-K with the SEC to furnish a company announcement dated November 11, 2026. The filing itself contains only administrative cover-page information and an exhibit index; the substantive content of the announcement is not included in the provided text.

View full filing details →
6-K · OtherNov 12, 2026

Genmab A/S filed a Form 6-K with the SEC to furnish its updated Articles of Association as an exhibit. The filing was signed by Executive Vice President & Chief Financial Officer Anthony Pagano.

View full filing details →
6-K · OtherNov 12, 2026

Genmab A/S filed a Form 6-K with the SEC for the month of November 2026, referencing a company announcement dated November 12, 2026 as Exhibit 99.1. The filing itself contains only administrative cover-page information and the exhibit index; the substantive content of the announcement is not included in the provided text.

View full filing details →
6-K · OtherNov 10, 2026

Genmab A/S filed a Form 6-K with the SEC on November 10, 2026, attaching a company announcement dated the same day. The filing itself contains no substantive financial or operational details beyond the exhibit reference.

View full filing details →
6-K · OtherNov 5, 2026

Genmab reported Q3 2026 financial results with revenue up 22% to $3,238 million for the first nine months, driven by higher DARZALEX and Kesimpta royalties and EPKINLY sales. The company also announced positive Phase 3 topline results for epcoritamab, Rina-S, and petosemtamab, supporting multiple regulatory submissions and potential launches in 2027.

View full filing details →
Revenue for first nine months of 2026: $3.2B, Royalty revenue for first nine months of 2026: $2.7B, DARZALEX net sales by J&J for first nine months of 2026: $12.4B, EPKINLY/TEPKINLY global net sales for first nine months of 2026: $491.0M, Operating profit for first nine months of 2026: $986.0M, Adjusted operating profit for first nine months of 2026: $1.1B
6-K · OtherOct 28, 2026

Genmab A/S filed a Form 6-K with the SEC furnishing a company announcement dated October 28, 2026. The filing itself contains only administrative cover-page information and an exhibit index; the substantive content of the announcement is not included in the provided text.

View full filing details →
6-K · OtherOct 23, 2026

Genmab A/S filed a Form 6-K with the SEC on October 23, 2026, referencing a company announcement dated the same day as Exhibit 99.1. The filing itself contains only administrative cover-page information and does not disclose the substance of the announcement.

View full filing details →
6-K · OtherOct 13, 2026

Genmab A/S filed a Form 6-K with the SEC on October 13, 2026, referencing a company announcement dated the same day as Exhibit 99.1. The filing itself contains only administrative cover-page information and does not disclose the substantive content of the announcement.

View full filing details →
6-K · OtherOct 7, 2026

Genmab A/S filed a Form 6-K with the SEC containing a company announcement dated October 7, 2026. The filing itself provides no substantive details beyond the exhibit reference and signature by CFO Anthony Pagano.

View full filing details →

Showing 10 of 18 filings. See all filings with SEPT X-Ray

Has GMAB ever done a stock split?

No stock splits are recorded for GMAB.

Get Real-Time GMAB Intelligence

SEPT X-Ray combines SEC filings with price targets, support/resistance levels, and smart money tracking — updated every 30 minutes.

Try SEPT X-Ray Free

More GMAB Research

GMAB FundamentalsGMAB AnalysisSEPT Academy
Share:XRedditFacebookLinkedIn
© SEPT Investing. Filing summaries are extracted automatically from SEC filings and may contain errors. Always verify with official SEC EDGAR filings. Trading involves risk.